Skip to content
10-Q

Quarterly Report

vTv Therapeutics Inc. VTVT

0001641489-26-000020

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Operating Cash Flow Q1 2026 · Mar 31, 2026 $9.15M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$5.69M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $98.09M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $88.93M
Stockholders Equity Q1 2026 · Mar 31, 2026 $89.96M
Stockholders Equity Q1 2026 · Dec 31, 2025 $64.44M
Current Liabilities Q1 2026 · Mar 31, 2026 $6.88M
Current Liabilities Q1 2026 · Dec 31, 2025 $6.64M
Total Liabilities Q1 2026 · Mar 31, 2026 $8.85M
Total Liabilities Q1 2026 · Dec 31, 2025 $25.46M
Current Assets Q1 2026 · Mar 31, 2026 $98.81M
Current Assets Q1 2026 · Dec 31, 2025 $89.89M
Total Assets Q1 2026 · Mar 31, 2026 $98.81M
Total Assets Q1 2026 · Dec 31, 2025 $89.9M
Sga Expense Q1 2026 · Mar 31, 2026 $4.6M
Sga Expense Q1 2026 · Mar 31, 2025 $3.67M
Rd Expense Q1 2026 · Mar 31, 2026 $8.98M
Rd Expense Q1 2026 · Mar 31, 2025 $2.83M
Net Income Q1 2026 · Mar 31, 2026 $24.13M
Net Income Q1 2026 · Mar 31, 2025 −$5.09M
Operating Income Q1 2026 · Mar 31, 2026 $23.26M
Operating Income Q1 2026 · Mar 31, 2025 −$6.5M
Revenue Q1 2026 · Mar 31, 2026 $36.84M
Revenue Q1 2026 · Mar 31, 2025 $0